The glycoproteomics firm is using its mass spec platform for ovarian cancer and immunotherapy tests as well as service work for pharma and other partners.
For the three months ended Sept. 30, the firm said that total revenues fell to $1.2 million from $1.3 in the year-ago quarter with OVA1 volumes essentially flat.
Investors in the company, formerly known as Vermillion, have agreed to purchase $11 million in unregistered common stock at a price of $3.50 per share.
Revenues rose to $1.2 million on OVA1 test volumes of 3,654, up 58 percent from Q1 2019, as the company maintained growth despite the SARS-CoV-2 pandemic.